Why the study?
Does the nitric oxide synthase/guanylate cyclase pathway modulate phenylephrine-induced contractility in the rat vas deferens?
Does the nitric oxide synthase/guanylate cyclase pathway modulate phenylephrine-induced contractility in the rat vas deferens?
In the rat vas deferens, nitric oxide potentiates the contractility induced by adrenergic stimulation despite its known relaxant properties.
Supports NO potentiation of adrenergic contractility in rat vas deferens; hypothesis-generating and should not yet change practice.
The involvement of the nitric oxide synthase/soluble guanylate cyclase pathway on the modulation of phenylephrine-induced contractility in the rat vas deferens was investigated. Phenlylephrine-concentration response curves were obtained in absence and in presence of inhibitors, N(G)-Nitro-L-arginine (L-NOARG), NG-Nitro-L-arginine methyl esther (L-NAME) or N(G)-monomethyl-L-arginine (L-NMMA) or GC inhibitior, 1H-(1,2,4)-oxadiaziol-(4,3-a)quinoxalin-1-one (ODQ) or nitric oxide donor, 3-morpholinosydnonimine hydrochloride (SIN-1) alone or together with L-NMMA or ODQ. Both nitric oxide synthase and GC inhibitors reduced the Phe-Emax. SIN-1 alone did not change phenylephrine-induced responses and it could reverse the L-NMMA effect but not ODQ effect. The reduction of the phenylephrine-induced contractility obtained in consequence of the inhibition of the nitric oxide/GC pathway suggest that, in the rat vas deferens, despite its well identified relaxant properties, nitric oxide potentiates the contractility induced by adrenergic stimulation.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: